TGTX — TG Therapeutics Inc

TG Therapeutics Inc (TGTX) is a biotechnology company listed on NASDAQ. It is led by Michael S. Weiss Esq., J.D., based in 3020 Carrington Mill Blvd., Morrisville, NC, United States, 27560, with about 399 employees. TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

Latest reported TGTX revenue for 2025-09-30 was $161.7M. Net income was $390.9M. Revenue was up 14.6% from 2025-06-30 to 2025-09-30. TGTX currently screens at market cap $7.88B and trailing P/E 18.0.

Use this TGTX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the TGTX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the TGTX SEC filings page. Lician reads the product cache first so this HTML stays unique to TG Therapeutics Inc even when a live quote feed is slow.